Back to Search
KAMALJIT ATWAL, DO
DO
Pulmonary Disease Physician
NPI: 1821053356IndividualAccepts Medicare
Specialties, Licenses & Credentials
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
DO19518(OR)
Education
DES MOINES UNIVERSITY OF OSTEOPATHIC MEDICINE AND HEALTH SCIENCES
Class of 1994
Research & Publications (20)
Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
PMID 19665893·Bioorg Med Chem Lett·2009
7-preclinical
Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.
PMID 19541481·Bioorg Med Chem Lett·2009
7-preclinical
Dihydropyrazolopyrimidine inhibitors of K(V)1.5 (I(Kur)).
PMID 19004630·Bioorg Med Chem Lett·2008
7-preclinical
Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
PMID 18998662·J Med Chem·2008
7-preclinical
Synthesis and evaluation of acylguanidine FXa inhibitors.
PMID 18644722·Bioorg Med Chem Lett·2008
8-other
Pyrano-[2,3b]-pyridines as potassium channel antagonists.
PMID 18374568·Bioorg Med Chem Lett·2008
7-preclinical
Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
PMID 17937986·Bioorg Med Chem Lett·2007
4-observational
Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
PMID 17855089·Bioorg Med Chem Lett·2007
8-other
Benzopyran sulfonamides as KV1.5 potassium channel blockers.
PMID 17462888·Bioorg Med Chem Lett·2007
8-other
Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
PMID 16870436·Bioorg Med Chem Lett·2006
7-preclinical
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.
PMID 16213711·Bioorg Med Chem Lett·2005
8-other
Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase.
PMID 15713402·Bioorg Med Chem Lett·2005
7-preclinical
Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.
PMID 15371268·Am J Physiol Heart Circ Physiol·2004
7-preclinical
Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.
PMID 15013017·Bioorg Med Chem Lett·2004
7-preclinical
N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase.
PMID 15013016·Bioorg Med Chem Lett·2004
7-preclinical
Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.
PMID 14971888·J Med Chem·2004
7-preclinical
One-pot synthesis and conformational features of n,n'-disubstituted ketene aminals.
PMID 14703396·J Org Chem·2004
8-other
Aminoimidazoles as bioisosteres of acylguanidines: novel, potent, selective and orally bioavailable inhibitors of the sodium hydrogen exchanger isoform-1.
PMID 14684323·Bioorg Med Chem Lett·2004
8-other
Tetrahydronaphthalene-derived amino alcohols and amino ketones as potent and selective inhibitors of the delayed rectifier potassium current IKs.
PMID 14684307·Bioorg Med Chem Lett·2004
7-preclinical
Dynamic capillary coatings with zwitterionic surfactants for capillary isoelectric focusing.
PMID 12866868·Analyst·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10201 SE MAIN ST STE 11
PORTLAND, OR 97216 - Phone
- (503) 253-2248
Quick Facts
- NPI
- 1821053356
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile